biotech · Alzheimer Disease · Major Depressive Disorder · CGTX
Cognition Therapeutics
COGNITION THERAPEUTICS INC
Cognition Therapeutics is a biotech organization headquartered in Purchase, USA. It trades on NYSE under ticker CGTX. Primary therapeutic focus areas include Alzheimer Disease, Major Depressive Disorder, Primary biliary
2500 Westchester Ave, Purchase, New York 10577, US HQ
2007 Founded
32 Employees
Public company Type
CGTX · NYSE Ticker
Company details
- Status
- Public
- HQ
- 2500 Westchester Ave, Purchase, New York 10577, US
- Founded
- 2007
- Employees
- 32
- Programs
- 33
- Drugs
- 26
- Patents
- 12
CT1812
Phase 2 · small molecule · Early Alzheimer's Disease
CT1812 for Early Alzheimer's Disease is a Phase 2 program (small_molecule) at COGNITION THERAPEUTICS INC with 1 ClinicalTrials.gov record(s).
Internal code COG0203
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- COGNITION THERAPEUTICS INC
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Early Alzheimer's Disease
- Status
- active
- Trials
- 1